-
GSK Consumer announces next big allergy switch for 2017
WARREN, N.J. - GSK Consumer Healthcare on Wednesday unveiled the next big switch that will hit allergy aisles in 2017 - the U.S. Food and Drug Administration approved the company's Flonase Sensimist Allergy Relief (fluticasone furoate, 27.5 mcg spray) as an over-the-counter treatment for symptoms associated with seasonal and perennial allergies.
Previously available by prescription as Veramyst, Flonase Sensimist is the latest Rx-to-OTC switch from GSK.
-
Flonase continues market strength
GSK Consumer Healthcare’s Flonase allergy remedy was the single greatest generator of incremental dollars for the 52 weeks ended May 15 across total U.S. multi-outlets, according to IRI data, with $345.2 million in sales on 209.9% growth. The question headed into its second year on OTC shelves is can it maintain its momentum now that private-label competition for Flonase has reached store shelves.